MI4A Market Information for Access to Vaccines

Improving access to affordable supply

Fair Pricing Forum, Johannesburg, April 12th, 2019

Johanna FIHMAN, WHO

© AMRO/PAHO, S Mey-Schmidt
Vaccine price transparency into context

The access landscape for vaccines:

- Gavi the vaccine Alliance support to the poorest countries (73) of the world
- The Bill & Melinda Gates Foundation and other entities (e.g. PATH) are active in market shaping in the Gavi market
- UNICEF & PAHO act as pooled/centralised procurement entities

Vaccine Price is key to sustainable immunization programmes
Yet it remains one of main obstacles to access
The WHA has repeatedly called for action on access to vaccine supply

- Total of 50 WHA Global Resolutions on access to medicines and vaccines + 45 regional Resolutions
- Over 60 member states spoke at 71st WHA on vaccine shortages, high prices, continuous need for information/support
- WHO Access Roadmap for 2019-2023 to enhance access to medicine and vaccines aligned with GPW13
MI4A as part of the solution

How do we work?
Access efforts: the missing segment

<table>
<thead>
<tr>
<th>Vaccine Category</th>
<th>LICs</th>
<th>LMICs</th>
<th>UMICs</th>
<th>HICs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measles-containing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTwP-HepB-Hib</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rota</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mening</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTP-containing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DT, Td, TT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bOPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: MI4A, GVAMM, UNICEF, Gavi, PAHO RF

Increasing GNI per capita

Procurement:
- Gavi-financed, UNICEF procured
- UNICEF-procured
- PAHO-procured
- Self-procured
Self-procured/funded vaccines represent about 60% of market volumes and 90% of the value.
MI4A to inform global and local access strategies

Enhance the **understanding** of *global* vaccine demand, supply and pricing dynamics and identify affordability and shortage risks

**Convene** global health partners to define strategies and guidance to address identified risks – *focus self-procuring/funding countries*

Strengthen **national and regional** market understanding for improved access to vaccines supply

*MI4A builds on the success of the V3P project and on 2017 successful BCG and D&T pilots*
MI4A key areas of action

1. A Collection & quality control of price/procurement/demand/supply data
   Outputs: yearly updated data set with global vaccine market information made public

3. B Providing technical assistance to countries
   Output: countries supported to make appropriate use of available information

3. A Developing guidelines/tools
   Output: e.g. transitioning country pricing fact sheet; MI4A country purchase fact sheets; MI4A regional fact sheets

1. B In depth global market analysis
   Outputs:
   - 2 global vaccine specific market studies yearly
   - Global vaccine market report
   - Study of specific market dynamics

2. A Information sharing ecosystem
   Output: policy makers, regulators, industry, countries, partners use information on relevant market dynamics to inform their actions

2. B Guidance & strategies to enhance affordability and availability
   Output: E.g. TT-Td replacement; SAGE recommendation on best use of scarce HPV supply
Key achievements

What progress have we made up to present?

Health agents are pictured during the first day of the yellow fever vaccination campaign in Kinshasa, on August 17, 2016.

© WHO / Eduardo Soteras Jalil
Great advances in vaccine market intelligence

Number of countries reporting over time by region & share by income group

Source: WHO JRF/V3P 2018 – all data available at: www.who.int/immunization/MI4A

Up from 47% last year
Improved understanding of cross cutting market dynamics

Factors that influence price for self-procured purchases - both GNI per capita and volume showed statistically significant associations with price:

- On average, a 1 million-dose increase in the vaccine purchase volume is associated with a 1.7% decrease in the vaccine price
- On average, a $1,000 increase in a country’s GNI per capita is associated with a 5.5% increase in the price of a purchased vaccine
- The relationship between price and contract length is not significant

Source: MI4A, for more information see Global Vaccine Market Report 2018 available at www.who.int/immunization/MI4A
Increase in use of data

MI4A database used to inform negotiations in HPV Price

Data used in market research in Baltic States

Use price as input to country wastage calculator

MI4A data to inform decisions on new vaccine introduction in MICS
Looking ahead

Key priorities
# Country engagement

<table>
<thead>
<tr>
<th>OBJECTIVES</th>
<th>TARGET</th>
<th>TACTICS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENHANCE DATA COLLECTION</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| • Ensure continued reporting  
• Target non reporting countries  
• Move towards prospective data collection | GLOBAL | Outreach, dissemination strategy, communication  
Targeted advocacy  
Process for data collection out of JRF |
| **ENHANCE AND DOCUMENT USE OF MI4A DATA** | Self procuring MICS | Document and analyze use  
Priority countries: new intro, low coverage  
MI4A reports and factsheets, meetings/workshops |

**PARTNERS KEY:** MSF, Save the Children – focus on advocacy  
UNICEF – coordinated support to countries  
WHO regional and country support  

Includes
Thank you!
In depth global understanding of 4 markets dynamics and risks